4.3 Review

Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial

Journal

SURGERY TODAY
Volume 47, Issue 9, Pages 1060-1071

Publisher

SPRINGER
DOI: 10.1007/s00595-017-1480-3

Keywords

Surgical site infection; Absorbable suture; Silk suture; Surgery; Randomized prospective clinical trial

Categories

Funding

  1. Japan Surgical Society Clinical Investigation Project Award
  2. Health Labour Science Research Grant [Rinsho-Ippan-006]

Ask authors/readers for more resources

Background The use of absorbable sutures in wound closure has been shown to reduce the incidence of surgical site infection (SSI); however, there is no evidence that the intra-abdominal use of absorbable rather than silk sutures reduces the incidence of SSI after gastrointestinal surgery. We report the findings of a phase II trial, designed to evaluate the impact of the intra-abdominal use of absorbable sutures on the incidence of SSI. Methods At 19 Japanese hospitals, 1147 patients undergoing elective gastrectomy, colorectal surgery, hepatectomy, or pancreaticoduodenectomy (PD) were randomly assigned to absorbable or silk intra-abdominal suture groups. The primary efficacy endpoint was the incidence of SSI. The secondary efficacy endpoints were the locations of SSI, time to resolution of SSI, length of hospital stay, and the incidence of bile leakage in hepatectomy and pancreatic fistula. Results The incidence of SSI was 11.3%, 15.5%, 11.3%, and 36.9% after gastrectomy, colorectal surgery, hepatectomy, and PD, respectively. The incidence of SSI was higher in the absorbable suture group than in the silk suture group for all the surgical procedures, but the difference was not significant. Conclusion The intra-abdominal use of absorbable sutures did not have enough of an effect on the reduction of SSI in this phase II trial to justify the planning of a large-scale phase III trial.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

Claire Gallois, Qian Shi, Jeffrey P. Meyers, Timothy Iveson, Steven R. Alberts, Aimery de Gramont, Alberto F. Sobrero, Daniel G. Haller, Eiji Oki, Anthony Frank Shields, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Greg Yothers, Caroline Kelly, Ioannis Boukovinas, Roberto Labianca, Frank A. Sinicrope, Ioannis Souglakos, Takayuki Yoshino, Jeffrey A. Meyerhardt, Thierry Andre, Demetris Papamichael, Julien Taieb

Summary: Whether early discontinuation of all treatment or early discontinuation of oxaliplatin could worsen the prognosis in patients with stage III CC remains unknown.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Biochemistry & Molecular Biology

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Daisuke Kotani, Eiji Oki, Yoshiaki Nakamura, Hiroki Yukami, Saori Mishima, Hideaki Bando, Hiromichi Shirasu, Kentaro Yamazaki, Jun Watanabe, Masahito Kotaka, Keiji Hirata, Naoya Akazawa, Kozo Kataoka, Shruti Sharma, Vasily N. Aushev, Alexey Aleshin, Toshihiro Misumi, Hiroya Taniguchi, Ichiro Takemasa, Takeshi Kato, Masaki Mori, Takayuki Yoshino

Summary: Circulating tumor DNA (ctDNA) analysis can help with risk stratification and treatment decisions for patients with resectable colorectal cancer (CRC). The study found that postsurgical ctDNA positivity was associated with higher recurrence risk and was the most significant prognostic factor for patients with stage II or III CRC. Furthermore, ctDNA positivity identified patients who derived benefit from adjuvant chemotherapy.

NATURE MEDICINE (2023)

Article Surgery

Alterations in the gut microbiome in patients with esophageal carcinoma in response to esophagectomy and neoadjuvant treatment

Hirofumi Hasuda, Tetsuo Ikeda, Yutaka Makizaki, Haruka Yokota, Yoshiki Tanaka, Hiroshi Ohno, Mototsugu Shimokawa, Hiroya Matsuoka, Yasue Kimura, Eiji Oki, Tomoharu Yoshizumi

Summary: The gut microbiome of patients with esophageal squamous cell carcinoma is altered, with differences in microbial diversity and composition compared to healthy individuals. These alterations are more pronounced after surgical intervention.

SURGERY TODAY (2023)

Article Oncology

Trifluridine/tipiracil plus bevacizumab (BEV) vs. fluoropyrimidine-irinotecan plus BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial

Yasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, Masato Nakamura, Jun Watanabe, Hitoshi Ojima, Akitaka Makiyama, Masahito Kotaka, Hiroki Hara, Yoshinori Kagawa, Naotoshi Sugimoto, Hisato Kawakami, Atsuo Takashima, Takeshi Kajiwara, Eiji Oki, Yu Sunakawa, Soichiro Ishihara, Hiroya Taniguchi, Takako Eguchi Nakajima, Satoshi Morita, Kuniaki Shirao, Naruhito Takenaka, Daisuke Ozawa, Takayuki Yoshino

Summary: This study assessed the noninferiority of trifluridine/tipiracil (FTD/TPI) plus bevacizumab as second-line treatment for metastatic colorectal cancer (mCRC) compared to fluoropyrimidine and irinotecan plus bevacizumab. The results showed that FTD/TPI plus bevacizumab did not demonstrate superiority over the control group in mCRC second-line treatment.

BRITISH JOURNAL OF CANCER (2023)

Article Engineering, Electrical & Electronic

Shared Backup Allocation Model of Middlebox Based on Workload-Dependent Failure Rate

Han Zhang, Fujun He, Eiji Oki

Summary: This paper proposes a shared backup allocation model for middleboxes considering the workload-dependent failure rate of backup servers. The simulated annealing algorithm is used to solve this problem. Experimental results show that the proposed model can reduce the maximum unavailability by an average of 29% compared to the baseline model under different conditions.

IEICE TRANSACTIONS ON COMMUNICATIONS (2023)

Article Oncology

Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial

Qingjiang Hu, Eiji Oki, Teppei Yamada, Tomomi Kashiwada, Hideto Sonoda, Masato Kataoka, Hirofumi Kawanaka, Yasushi Tsuji, Akitaka Makiyama, Yuichiro Nakashima, Mitsuhiko Ota, Yasue Kimura, Tomoharu Yoshizumi

Summary: By analyzing the genomic characteristics of HER2-positive and negative gastric cancer, we found that several gene alterations in the HER2 pathway may be the potential mechanism underlying trastuzumab resistance, and HER2-negative gastric tumors with ARID1A mutation may be sensitive to immune checkpoint inhibitors.

CANCER MEDICINE (2023)

Article Oncology

Clinical outcomes of intensive versus less intensive first-line chemotherapy for metastatic colorectal cancer

Kentaro Yamazaki, Satoshi Yuki, Eiji Oki, Fumikazu Sano, Misako Makishima, Kenichi Aoki, Tetsutaro Hamano, Kouji Yamamoto

Summary: In this study, the baseline characteristics and efficacies of intensive and less intensive therapies for metastatic colorectal cancer were compared. Patient age and daily activity levels were found to be important factors in determining treatment intensity.

FUTURE ONCOLOGY (2023)

Article Oncology

Phase II clinical trial to study the safety and efficacy of combined S-1+oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients

Mitsuhiko Ota, Hiroshi Saeki, Hideo Uehara, Yoshiko Matsuda, Satoshi Tsutsumi, Tetsuya Kusumoto, Hisateru Yasui, Yasunari Ubukata, Shohei Yamaguchi, Hiroyuki Orita, Naoki Izawa, Saburo Kakizoe, Mototsugu Shimokawa, Tomoharu Yoshizumi, Yoshihiro Kakeji, Masaki Mori, Eiji Oki

Summary: This study evaluates the safety and efficacy of neoadjuvant chemotherapy with SOX130 in older patients with locally advanced gastric cancer. The results show that NAC-SOX130 is feasible for older patients, although careful monitoring of adverse events is necessary.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition

Saori Mishima, Yoichi Naito, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama, Motohiro Kato, Hirotsugu Kenmotsu, Yasuhiro Kodera, Keigo Komine, Takafumi Koyama, Osamu Maeda, Mitsuru Miyachi, Hiroshi Nishihara, Hiroyuki Nishiyama, Shouichi Ohga, Wataru Okamoto, Eiji Oki, Shigeru Ono, Masashi Sanada, Ikuo Sekine, Tadao Takano, Kayoko Tao, Keita Terashima, Katsuya Tsuchihara, Yasushi Yatabe, Takayuki Yoshino, Eishi Baba

Summary: This article summarizes the efficacy of immune checkpoint inhibitors in the treatment of dMMR advanced solid tumors and proposes eight recommendations for proper MMR testing and selection of patients for immunotherapy.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Left recurrent nerve lymph node dissection in robotic esophagectomy for esophageal cancer without esophageal traction

Tomonori Nakanoko, Yasue Kimura, Keita Natsugoe, Kentaro Nonaka, Sho Nambara, Qingjiang Hu, Ryota Nakanishi, Mitsuhiko Ota, Eiji Oki, Tomoharu Yoshizumi

Summary: Due to the interference of the robotic arm, the dissection of the left recurrent nerve lymph nodes during robotic surgery is difficult. In this study, we developed a method of LRLN dissection with natural space creation and evaluated its short-term results.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2023)

Article Surgery

Real-time telementoring with 3D drawing annotation in robotic surgery

Tomonori Nakanoko, Eiji Oki, Mitsuhiko Ota, Naoki Ikenaga, Yuichi Hisamatsu, Takeo Toshima, Takahiro Kanno, Kotaro Tadano, Kenji Kawashima, Kenoki Ohuchida, Hajime Morohashi, Yuma Ebihara, Koshi Mimori, Masafumi Nakamura, Tomoharu Yoshizumi, Kenichi Hakamada, Satoshi Hirano, Norihiko Ikeda, Masaki Mori

Summary: In this study, the usefulness of telementoring using 3D drawing annotations in robotic surgery was examined. The results showed that the 3D annotation group had a shorter working time, fewer retries, and higher scores on the evaluation of robot skills compared to the control group.

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2023)

Article Surgery

Esophagectomy for esophageal stricture with systemic sclerosis: a case report

Yuho Ebata, Yasue Kimura, Kentaro Nonaka, Sho Nambara, Qingjiang Hu, Ryota Nakanishi, Tomonori Nakanoko, Mitsuhiko Ota, Eiji Oki, Tomoharu Yoshizumi

Summary: Esophagectomy is a valuable option for treating esophageal strictures in patients with SSc. Therefore, surgical approaches should be established for SSc patients.

SURGICAL CASE REPORTS (2023)

Meeting Abstract Oncology

The significance of ATR as a therapeutic target in combination with DNA replication stress-inducing drugs

Kentaro Nonaka, Makoto Iimori, Eiji Oki, Yoshihiko Maehara, Tomoharu Yoshizumi, Hiroyuki Kitao

CANCER SCIENCE (2023)

Meeting Abstract Oncology

Precision Oncology for Surgery without Recurrence

Eiji Oki

CANCER SCIENCE (2023)

Meeting Abstract Oncology

Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer

Qingjiang Hu, Takaaki Masuda, Eiji Oki, Koshi Mimori, Tomoharu Yoshizumi

CANCER SCIENCE (2023)

No Data Available